EP2825260A1 - Vorrichtung zur therapeutischen behandlung und verfahren zur steuerung einer behandlungsvorrichtung - Google Patents

Vorrichtung zur therapeutischen behandlung und verfahren zur steuerung einer behandlungsvorrichtung

Info

Publication number
EP2825260A1
EP2825260A1 EP13709120.3A EP13709120A EP2825260A1 EP 2825260 A1 EP2825260 A1 EP 2825260A1 EP 13709120 A EP13709120 A EP 13709120A EP 2825260 A1 EP2825260 A1 EP 2825260A1
Authority
EP
European Patent Office
Prior art keywords
hifu
mark
pulse
transducer
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13709120.3A
Other languages
English (en)
French (fr)
Other versions
EP2825260B1 (de
Inventor
Sylvain Yon
Francois Lacoste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theraclion SA
Original Assignee
Theraclion SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraclion SA filed Critical Theraclion SA
Priority to EP13709120.3A priority Critical patent/EP2825260B1/de
Publication of EP2825260A1 publication Critical patent/EP2825260A1/de
Application granted granted Critical
Publication of EP2825260B1 publication Critical patent/EP2825260B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N7/02Localised ultrasound hyperthermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00845Frequency
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00886Duration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37Surgical systems with images on a monitor during operation
    • A61B2090/378Surgical systems with images on a monitor during operation using ultrasound

Definitions

  • the present invention relates to a device for therapeutic treat ⁇ ment and a method for controlling a therapeutic treatment device according to the independent claims.
  • the invention concerns treatments by focused high intensity ultrasounds (HIFU) .
  • HIFU focused high intensity ultrasounds
  • an acoustic treatment transducer emits concentrated acoustic waves into a target tissue. These waves are absorbed by the tissue, which provokes a temperature rise in the tissue in the focal region. This temperature elevation in turn allows the creation of a necrosis and thereby allows destruction of living tissue at a distance without any direct contact.
  • Some HIFU systems that are guided by ultrasound use constant in ⁇ tensity values to obtain a correct treatment efficacy. Such an approach is only possible when the target to be treated is very close to the HIFU source. In cases when the HIFU beam has to go through skin and potentially other layers of tissue before reaching the targeted area the use of constant values to adapt the treatment efficacy would not allow to compensate for the different configurations of the ultrasound path which would lead to very large variations of the acoustical intensities in the targeted area.
  • hyperechoic marks Another approach is to use the occurrence of hyperechoic marks (HEM) as an indicator for the local changes of tissue properties.
  • HEM hyperechoic marks
  • Such an approach has for example been described in WO 2010/020730 or WO 2011/036485. Due to the fact that the detec ⁇ tion of the apparition of hyperechoic marks is not easy and hy ⁇ perechoic marks occur in a temperature range of approximately 80 °C to 100 °C, the detection of hyperechoic marks is not consid ⁇ ered sufficiently reliable for the control of HIFU treatments.
  • a device for therapeu ⁇ tic treatment comprising at least an acoustic treatment trans ⁇ ducer, at least one detector and at least one means for time measurement or means for detecting the frequency of appearance of changes of tissue properties.
  • the acoustic treatment trans ⁇ ducer is able to emit high intensity waves (HIFU) toward a tar ⁇ get in order to treat the target, wherein the high intensity waves have a focal point.
  • the detector is able to detect a change of tissue properties caused by the high intensity waves at the target in a manner basically known to the skilled person.
  • the means for time measurement is able to measure the time t mark from the beginning of emission of a pulse of HIFU until changes of tissue properties are detected.
  • changes of tissue properties are defined to be any sign of a change in the acoustic properties of tissue under treatment.
  • the invention refers to observa ⁇ tions of changes of tissue per se.
  • the change in the properties of the tissue without any changes of the environ ⁇ ment within the tissue is observed, in particular, e.g. without the presence of any additional agents such as contrast agents.
  • the changes in acoustic properties are hyperechoic marks.
  • the change in the acoustic properties of the tissue can be broadband emissions, which can occur due to cavitation.
  • hyperechoic marks are a manifestation of increased acoustic reflectivity of the tissue in the treated area, notably originating from newly created gas bubbles.
  • such changes can for example stem from temperature increase and tis ⁇ sue boiling, inertial cavitation or tissue hardening.
  • the temperature increase and tissue boiling caused thereby can be considered as a phase change of the tissue per se which can be observed in accordance with the present invention.
  • Hyperechoic marks may reflect the sudden occurrences of bubbles in the tissue, which will locally increase the reflection of in ⁇ coming ultrasonic waves back to the transducer. Those reflected waves may in turn be detected by whitening on the ultrasonic im ⁇ age of the treated area or by a surge in the reflected electri ⁇ cal signal to the HIFU transducer.
  • the device allows for an indirect control of the HIFU treatment by means of measuring a time which consequently leads to a reli ⁇ able but nevertheless cost efficient device.
  • the power P e and/or the pulse duration t on of the HIFU transducer is adapted to obtain an optimal treatment result.
  • t Ma r k values may vary from one pulse to the other. Since HIFU pulses are also limited in time (typically a few seconds) , this leads to situa ⁇ tions where changes in tissue properties do only appear for some pulses.
  • IQR Interquartile Range
  • P e represents either a constant value of electrical power for the duration of the pulse, or a variable power law P e (t) which by definition is not null over the pulse duration t on -
  • the detector can comprise a acoustic imaging transducer, preferably a second acoustic imaging transducer, able to emit waves to provide an imaged representation of the target and of its en ⁇ vironment .
  • the imaged representation of the target can be provided before, during, or after the emission of the power waves from the high intensity transducer.
  • the HIFU impact at the target can be controlled in a cost-effective way.
  • the focal point of the emitted HIFU waves can be in an ultra ⁇ sound imaging plane of the second acoustic imaging transducer.
  • the imaging transducer enables to detect the occurrence of changes of tissue properties directly at the target without any delay.
  • the detector can comprise a device for detection of variation of pattern of interference during HIFU pulse as for example de ⁇ scribed in WO 2010/020730.
  • the device detects changes of tissue properties, in particular hyperechoic marks, by means of the detection of a change of structure of the interference image, wherein the interference image is created due to an interference of the HIFU transducer waves with the imaging transducer waves.
  • a device for therapeutic treatment comprising an acoustic treatment transducer a radio fre ⁇ quency generator generating a radiofrequency signal to power the acoustic treatment transducer and a detector.
  • the detector includes a radiofrequency directional coupler able to detect the characteristic features of the reflected radiofrequency signal.
  • the radiofrequency coupler is arranged on the power line of the HIFU transducer, which will allow the separation between the forward radiofrequency power (used for therapeutic ultrasound generation by the transducer) and its reflected part.
  • the characteristics features of interest in the reflected signal may be its envelope, or its spectral content along with their respective evolution with time or other characteristic features of a radiofrequency signal.
  • a change in the reflected part of the radiofrequency signal is indicative of a local change of the tissue properties so that a monitoring of the reflected part of the radiofrequency signal is equivalent to monitoring changes of tissue properties, in particular hyperechoic marks.
  • t mark is represented by the delay between the onset of the pulse and the detected change in the radiofrequency signal.
  • Radiofrequency coupler which can be applied for the above mentioned purpose is the Werlatone 40dB Dual Direc ⁇ tional Coupler, Model C5571.
  • Werlatone 40dB Dual Direc ⁇ tional Coupler Model C5571.
  • the reverse power coupling port will be used.
  • Such a measurement of the occurrence of changes of tissue prop ⁇ erties allows for a cost-efficient and easy way to either only detect the occurrence of changes of tissue properties or pref ⁇ erably to determine the time until hyperechoic marks occurs, i.e. the determination of t mark .
  • the devices as can further comprise means for storage of a ref ⁇ erence curve and means for comparing measured values with a ref ⁇ erence curve.
  • a reference curve can be based on experience, on theoretical de ⁇ duction, on statistical evolutions or a combination thereof. Typically, one reference curve per clinical application is stored. Preferably, the reference curve contains expectancy val ⁇ ues for t mar k and/or t on in combination with an electrical power of the HIFU transducer. The reference curve may be calculated for different target depth or may include a derating factor al ⁇ lowing taking target depth into account
  • the device can comprise a display for displaying the time t mark to an operator.
  • the display enables the operator to adjust the power and the pulse duration of the HIFU transducer to obtain an optimal treatment result.
  • the device can comprise means for determining a power P e for sub ⁇ sequent HIFU pulses based on t mark .
  • the power P e for subsequent pulses is determined based on t mark by means of a ref ⁇ erence curve as described above.
  • Means for determining the power P e for subsequent pulses allow for an automatic adjustment based on the previous measurement and hence allow for an optimal treatment result.
  • the device can comprise several detectors, preferably at least two detectors .
  • ⁇ detectors eliminate the random error of one detection means. Hence, a measurement is more reliable and accu ⁇ rate.
  • different methods for detection of changes of tissue properties are used, e.g. one based on ultrasound imagery of the therapy beam and one based on the characteristic features of the reflected radiofrequency signal or passive cavitation de ⁇ tection.
  • This also eliminates method- immanent measuring errors.
  • the values of t mark determined by the different methods are preferably used as a basis for a resulting tmar k -value that is used for the determination of the power P e and/or pulse duration t on -
  • the device can comprise several means for time measurement and means for determining an average t mark or for determining a weighted average time from different t mark values.
  • the detector preferably provides an indication of occurrence of t mark as well as a confidence value of the accuracy of the detec ⁇ tion.
  • the confidence value is taken into account for determina ⁇ tion of the weighted average in a manner basically known to the skilled person.
  • the determination of a weighted average t mark enhances the accu ⁇ racy of the adjustment of the treatment power.
  • a method for controlling a therapeutic treatment device comprises a step of monitoring a HIFU treatment by a HIFU transducer of a target by means of measuring a time t mark , wherein the time t mark is the time from the beginning of emission of a HIFU pulse to detection of changes of tissue properties or by measuring the frequency of appearance of changes of tissue properties f mark -
  • t mark can be substituted by f mark -
  • the regulation of the treatment can be conducted by changing the power P e or the pulse duration t on - Furthermore, the time between pulses t 0ff and/or the special position of the pulses can be adapted . Since the time t mark is correlated to the intensity of the HIFU beam in the target zone, this method provides for a cost- efficient and easy control of a HIFU treatment.
  • the model expresses the temperature rise in the focus of a HIFU pulse by solving the bio-heat transfer equa ⁇ tion. During the pulse the increase in temperature ⁇ at time t is given by: a 4*k,
  • I in-situ intensity of the HIFU pulse which is roughly proportional to P e
  • Equation 2 can be inverted to obtain the time t at which a certain temperature increase ⁇ is obtained.
  • t mark is the time when the boiling temperature T boi i is reached and hyperechoic marks can be detected. In this case a tissue tem ⁇ perature of 37°C before application of the pulse is assumed.
  • Hyperechoic marks can be detected by measuring the variation of a pattern of interference during HIFU pulse.
  • the interference occurs between ultrasound waves from an imaging ultrasound transducer and an acoustic treatment transducer.
  • a measurement of the occurrence of hyperechoic marks by measur ⁇ ing the variation of a pattern of interference during a HIFU pulse does not interrupt the treatment and hence enhances the efficiency of the treatment. Furthermore, the measurement by an ⁇ other ultrasound transducer is cost-efficient.
  • a method for controlling a therapeutic treatment device prefera ⁇ bly as described above comprises the step of deter ⁇ mining changes of tissue properties by detecting characteristic features of a reflected radiofrequency (RF) signal by means of an radiofrequency (RF) coupler on a power line of the HIFU transducer .
  • RF radiofrequency
  • Such a method is reliable and simple and does not require a sup ⁇ plemental transducer to achieve the goal of observing a HIFU pulse .
  • the changes of tissue properties can be detected by a acoustic imaging transducer, preferably a second acoustic imaging trans ⁇ ducer, able to emit waves to provide an imaged representation of the target and of its environment.
  • the therapeutic treatment device can be initialized, wherein the initialization is directed to the values of pulse duration t on and/or pulse power P e , whereby the initialization includes the steps of emitting at least one initial calibration HIFU pulse from an acoustic treatment transducer onto a target to be treated at an electrical power Pi.
  • the time t mark between the be ⁇ ginning of emission of the initial calibration HIFU pulse and detection of changes of tissue properties can be measured and the electrical power P e for subsequent pulses can be determined in order to obtain a predefined intensity of HIFU at the target.
  • the initialization can further be based on a theoretical value of Pi or a value based on experience or a combination thereof in ⁇ stead of or in addition to the initial calibration HIFU pulse.
  • the electrical power P e is determined based on the known vari ⁇ ables after initialization Pi and t mar k- In simple cases this could be a linear transformation or a proportional integral de ⁇ rivative (PID) . More generally a curve such as the one repre ⁇ senting equation (6) may be used. Since the bio-heat transfer equation is a differential equation in most of the cases, the adaptation of P e can be based on predefined curves for the spe ⁇ cific clinical application to get an accurate result.
  • the power P e of the HIFU pulse emitted from the acoustic treat ⁇ ment transducer can be adapted on the value of t mar k measured for the previous pulse or based on the evolution of t mark over several previous pulses and consequent adjustment of the electrical power P e and/or the time t on -
  • the adaption of the power P e based on one or more previous pulses enables the control of the treatment and hence leads to a safe and efficient treatment.
  • the power P e or t on of the HIFU-pulse emitted from the acoustic treatment transducer can be adapted based on the frequency of appearance of changes of tissue properties.
  • the adaption of the power P e or t on based on the frequency of ap ⁇ pearance of changes of tissue properties also enables the con ⁇ trol of the treatment and leads to a safe and efficient treat ⁇ ment .
  • the adjustment of the power based on t mar k or on the evolution of t mar k can be conducted while taking into account its inherent dis ⁇ persion by applying techniques inspired by statistical process control or filtering.
  • the method can comprise the following steps:
  • Figure 1 shows a schematic overview of a treatment device 1 ac ⁇ cording to the invention.
  • the device 1 is controlled by the user through a graphical user interface 7 (for instance a touchscreen) .
  • the processing unit 6 allows control of the interaction between the different subsys ⁇ tems .
  • An acoustic treatment transducer 2 emits high intensity acoustic waves (HIFU Beam) 2b onto a target 3.
  • the HIFU waves are focused onto the target 3 within a target area.
  • a radiofrequency genera ⁇ tor 8 provides the necessary radiofrequency power for generation of the HIFU beam. This radiofrequency generator 8 is controlled both in terms of power and timing by the processing unit 6.
  • An ultrasound imagery transducer 4 allows the observation of the target area and of the beam propagation, provided that its field of view 4b encompasses the HIFU beam focal point.
  • An ultrasound scanner 5 generates an image stream that is fed to the process ⁇ ing unit 6.
  • the reflected power signal is tapped on the radiofrequency power line by a radiofrequency directional coupler 9, and then fed to the processing unit 6 through an Analog to Digital Conversion (ADC) unit 10.
  • the processing unit 6 contains a circuit / algo ⁇ rithm to detect a change in the RF signal.
  • a counter / timer measures the time between the onset of the pulse and the instant the RF signal changes.
  • Figure 2 shows a preferred embodiment of the processing occur ⁇ ring in the processing unit 6.
  • the processing unit 6 provides a common timebase 11 that will allow synchronization of HIFU emission by radiofrequency generator 8 with detection of HEM. This feature allows deriving t Ma r k from the knowledge of HIFU pulse timing and detection of HEM.
  • the ultrasound image stream coming from ultrasound scanner 5 is fed to image processor 12 where a technique such as the one de ⁇ scribed in WO 2010/020730 allows retrieving information on the presence of interference patterns.
  • image processor 12 where a technique such as the one de ⁇ scribed in WO 2010/020730 allows retrieving information on the presence of interference patterns.
  • the output of this processor is fed to detector 13 which infers T Ma r k Imag along with detection quality information from the output of 13 and from the timing information provided by timebase 11.
  • the reflected radiofrequency signal provided by the analog to digital conversion unit 10 is processed by signal processor 14 in order to retrieve features such as its envelope and/or its spectral content. These features are then provided to HEM detec ⁇ tor 15, along with timing information from timebase 11 to obtain T Ma r k RF along with detection quality information.
  • Both T Mark Image and T Mark RF are then used by processor 16 to provide a best estimate of T Ma r k to the user through the graphic user in ⁇ terface 7.
  • direct outputs from processors 12 & 14 may be directly provided to the user for supplemental information.
  • An example of a reflected power signal is provided in Figure 3. This example yields a T mark RF of 2.67s.
  • the user is able to adapt treatment parameters (electrical power and t on ) and provide these to the control timebase for the next HIFU pulse.
  • T Ma rk information may be provided to a model and statistical processor 17, that will compute the best estimate of electrical power to use for the next pulse as described above.
  • a decision table can be used.
  • the intrinsic variability of t Mar k, o Is.
  • Pe Xt/ r ( n ) j_ s interpreted as the necessary electrical power that would have been necessary in the conditions of HIFU pulse n to
  • This information is also provided to the user through graphic user interface 7.
  • Figure 3 shows an example of a reflected signal envelope. This example yields a t mark of 2.67s.
  • Figure 4 shows the calculated time t mark to hyperechoic marks as a function of intensity for various boiling temperatures. This curve links in situ acoustical intensity with T Ma r k , and thus al ⁇ lows an indirect estimation of the in situ tissue characteris ⁇ tics. As can be seen in figure 4 and this is confirmed by ex ⁇ perience, t mark is sharply dependent upon the intensity.
  • Figure 5 shows the measured values of t mark over the power of the HIFU-device 1 (see Figure 1) for one given sample with homogene ⁇ ous coupling conditions. On each sample, a total of 15 to 25 HIFU pulses were delivered. In order to assess repeatability of T Ma r k in homogeneous situations, the following analysis was car ⁇ ried out:
  • t mark A(e B/Pe -l)
  • PeRef for the considered sample as the value for which the mathematical model intercepts t Mar kRef-
  • TMark (1) is measured through a first pulse with a given electrical power P e (1).
  • P e (1) is measured through a first pulse with a given electrical power P e (1).
  • Figure 7 shows a residual error distribution of T Ma rk est with the aforementioned model. Variance is less than Is, even though the data set includes a wide variety of coupling situations.
  • Figure 8 shows the usage of the statistical model over the course of a treatment.
  • the operator decides on the values of P e (n) , T on (n) for pulse number n.
  • the HIFU Pulse n at Pe (n) is applied.
  • T Mark (n) is measured dur ⁇ ing the application of the pulse.
  • new proposed value for next pulse are computed based on the measurement of T Ma rk(n) and the knowledge of P e (n) .
  • Step 24 is the end of the treatment.
  • the values P e (n) , T Mark (n) are collected to further improve the statistical model described in Figure 6.
  • the tissue In an attempt to always obtain hyperechoic marks during each pulse, it is proposed to expose the tissue to pulses with in ⁇ creasing power over time.
  • FIG. 9 shows examples of profiles of intensity vs. time. The process is carried out numerically. The figure shows examples of temperature profiles calculated with variable power. With pro ⁇ file "Lin-" the intensity is decreased linearly with time, y- ielding an essentially flat temperature after a 4 s warm-up pe ⁇ riod. This type of profile could be used if hyperechoic marks are detected at the beginning of the pulse (for example during the scanning phase of the treatment) and the operator wants to maintain an essentially constant temperature throughout the pulse .
  • T (t) is quickly (almost) linear: this means that there is high probability that T will reach T b0 ii during the pulse, meaning that hyperechoic marks will always be visible. This will help in regulating the power.
  • the example treatment procedure comprises two phases: An initialization phase and a treatment monitoring phase .
  • the initialization phase comprises the steps of: An initial calibration HIFU pulse at a given electrical power is emitted from the HIFU treatment transducer.
  • the initial power chosen is based on the knowledge of the specific clinical indi ⁇ cation and will make HEM appear within a time typically 1 to 2 seconds.
  • t mark is measured by device 1 as shown in Figure 1 & 2.
  • the electrical power to use in order to obtain a given value of t mark is chosen. This is done by the application of the theoretical model for t mark as described in Figures 4-6.
  • the treatment is then conducted based on the calculated value of the power of the HIFU transducer.
  • the values for t Ma r k are measured for each pulse.
  • the power can be adjusted based on the evolution of t mark .
  • the inherent dispersion is taken into account, for example by statistical process control. This can be done by the following decisions:
  • t mark is within lo of the goal value, keep current power P e . If T Mark remains twice in a row in the l-2o range (on the same side) , increase or decrease the power P e by 1 power x step' . If t Mark is over 2o range, the power P e is increase or decrease by 1 power 'step' .
  • a power x step' can be defined as 20% of the current value of electrical power: this provides a logarithmic scale of power values that is well adapted to the proposed exponential model linking T Mark and P e .

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
EP13709120.3A 2012-03-14 2013-03-14 Vorrichtung zur therapeutischen behandlung Active EP2825260B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13709120.3A EP2825260B1 (de) 2012-03-14 2013-03-14 Vorrichtung zur therapeutischen behandlung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12159445.1A EP2638932A1 (de) 2012-03-14 2012-03-14 Vorrichtung zur therapeutischen Behandlung und Verfahren zur Steuerung einer Behandlungsvorrichtung
EP13709120.3A EP2825260B1 (de) 2012-03-14 2013-03-14 Vorrichtung zur therapeutischen behandlung
PCT/EP2013/055209 WO2013135801A1 (en) 2012-03-14 2013-03-14 Device for therapeutic treatment and method for controlling a treatment device

Publications (2)

Publication Number Publication Date
EP2825260A1 true EP2825260A1 (de) 2015-01-21
EP2825260B1 EP2825260B1 (de) 2017-05-03

Family

ID=47878055

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12159445.1A Withdrawn EP2638932A1 (de) 2012-03-14 2012-03-14 Vorrichtung zur therapeutischen Behandlung und Verfahren zur Steuerung einer Behandlungsvorrichtung
EP13709120.3A Active EP2825260B1 (de) 2012-03-14 2013-03-14 Vorrichtung zur therapeutischen behandlung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12159445.1A Withdrawn EP2638932A1 (de) 2012-03-14 2012-03-14 Vorrichtung zur therapeutischen Behandlung und Verfahren zur Steuerung einer Behandlungsvorrichtung

Country Status (5)

Country Link
US (1) US10004921B2 (de)
EP (2) EP2638932A1 (de)
KR (1) KR102199318B1 (de)
CN (1) CN104168954B (de)
WO (1) WO2013135801A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2962730A1 (de) 2014-07-02 2016-01-06 Theraclion Therapeutische Behandlungsvorrichtung
PL3620801T3 (pl) * 2018-09-07 2021-07-19 Erbe Elektromedizin Gmbh Przyrząd do zasilania instrumentu medycznego oraz sposób monitorowania instrumentu
CN113117265B (zh) * 2019-12-30 2023-03-28 重庆融海超声医学工程研究中心有限公司 检测装置
KR102549574B1 (ko) * 2020-12-31 2023-06-30 (주)아이엠지티 집속 초음파 장치 및 초음파 신호 간 무간섭 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160136C (zh) * 2001-11-28 2004-08-04 北京源德生物医学工程股份有限公司 超声波热疗机及其焦点温度的预测方法
CN100542635C (zh) * 2005-01-10 2009-09-23 重庆海扶(Hifu)技术有限公司 高强度聚焦超声治疗装置和方法
US8016757B2 (en) * 2005-09-30 2011-09-13 University Of Washington Non-invasive temperature estimation technique for HIFU therapy monitoring using backscattered ultrasound
JP4279328B2 (ja) * 2007-05-07 2009-06-17 株式会社日立製作所 超音波撮像システム
US20120289827A1 (en) * 2008-05-06 2012-11-15 Ultrawave Labs, Inc. Multi-Modality Ultrasound and Radio Frequency Methodology for Imaging Tissue
ES2349550B1 (es) * 2008-08-20 2011-11-15 Centro Nacional De Investigaciones Cardiovasculares (Cnic) Inhibidores de la mek 1/2 para el tratamiento de la fibrosis peritoneal.
FR2935097A1 (fr) 2008-08-22 2010-02-26 Theraclion Dispositif de traitement therapeutique
GB0916635D0 (en) 2009-09-22 2009-11-04 Isis Innovation Ultrasound systems
WO2012006053A1 (en) * 2010-06-29 2012-01-12 Kullervo Henrik Hynynen Thermal therapy apparatus and method using focused ultrasonic sound fields
KR20130020421A (ko) * 2011-08-19 2013-02-27 삼성전자주식회사 초음파를 이용하여 치료부위의 온도를 모니터링하는 방법 및 장치, 초음파를 이용한 치료 및 진단 시스템

Also Published As

Publication number Publication date
KR102199318B1 (ko) 2021-01-06
CN104168954A (zh) 2014-11-26
CN104168954B (zh) 2017-10-27
WO2013135801A1 (en) 2013-09-19
US20150088039A1 (en) 2015-03-26
EP2825260B1 (de) 2017-05-03
EP2638932A1 (de) 2013-09-18
US10004921B2 (en) 2018-06-26
KR20150011799A (ko) 2015-02-02

Similar Documents

Publication Publication Date Title
JP5462167B2 (ja) Hifu治療中の組織変化モニタリングのためのシステム及び方法
CN110465008B (zh) 一种聚焦超声治疗系统
KR100932472B1 (ko) 병변조직을 검출하는 초음파 진단 시스템
JPH06189954A (ja) 非破壊形式の即ち非侵食形式の測定装置および生体の治療装置
WO2013135801A1 (en) Device for therapeutic treatment and method for controlling a treatment device
JP2009195617A (ja) 生体観測装置及び生体断層画像生成方法
JP5766604B2 (ja) 検査信号特性の分析によるhifu出力堆積の最適化およびフィードバック制御
WO2020191929A1 (zh) 质子治疗的监控方法、装置与系统
Freijo et al. Dictionary-based protoacoustic dose map imaging for proton range verification
CN106163414B (zh) 用于热损伤尺寸控制的基于归一化的位移差的方法
KR20130020054A (ko) 초음파 영상 생성 방법 및 그 초음파 시스템
JP6894088B2 (ja) 散乱体濃度計測装置及びその方法
CN112135567A (zh) 用于组织弹性监测和显示的剪切波幅值重建
KR20150096272A (ko) 조직의 온도 제어 방법 및 이를 이용한 온도 제어 장치
JP2001190587A (ja) 超音波治療装置
JP2010223770A (ja) 散乱体内部観察装置および散乱体内部観察方法
US8197524B2 (en) Energy irradiation device and method, control device and control method
CN115023266A (zh) 用于监视hifu治疗的设备
US20060241436A1 (en) Method and apparatus for non-invasive measurement of a temperature change inside a living body
WO2013132717A1 (ja) 超音波観測装置、超音波観測装置の作動方法および超音波観測装置の作動プログラム
Jenderka et al. Measurement of the total acoustic output power of HITU transducers
KR101781738B1 (ko) 주파수 변조 방식 체지방 이미지화를 이용한 비만도 분석 시스템 및 방법
JP6161447B2 (ja) 超音波治療装置
WO2020182939A1 (en) Device and method for evaluating dark field images
CN117677354A (zh) 热治疗组件

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160316

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 18/00 20060101ALN20160922BHEP

Ipc: A61N 7/02 20060101AFI20160922BHEP

Ipc: A61B 90/00 20160101ALN20160922BHEP

INTG Intention to grant announced

Effective date: 20161026

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YON, SYLVAIN

Inventor name: LACOSTE, FRANCOIS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 889312

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013020569

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170503

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 889312

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170503

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170803

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170803

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170903

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013020569

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170503

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170503

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230401

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240220

Year of fee payment: 12

Ref country code: GB

Payment date: 20240220

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240220

Year of fee payment: 12

Ref country code: FR

Payment date: 20240221

Year of fee payment: 12